Patents by Inventor Stefan Zeitler

Stefan Zeitler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
    Patent number: 9987328
    Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 5, 2018
    Assignee: CSL Behring GmbH
    Inventors: Stefan Zeitler, Marc Nolte, Stefan Schulte, Gerhard Dickneite, Ingo Pragst
  • FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES
    Publication number: 20160279195
    Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
    Type: Application
    Filed: April 28, 2016
    Publication date: September 29, 2016
    Inventors: Stefan ZEITLER, Marc NOLTE, Stefan SCHULTE, Gerhard DICKNEITE, Ingo PRAGST
  • Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
    Patent number: 9352016
    Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: May 31, 2016
    Assignee: CSL Behring GmbH
    Inventors: Stefan Zeitler, Marc Nolte, Stefan Schulte, Gerhard Dickneite, Ingo Pragst
  • von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
    Patent number: 9095564
    Abstract: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: August 4, 2015
    Assignee: CSL Behring GmbH
    Inventors: Gerhard Dickneite, Ingo Pragst, Henrique Lessa, Thorsten Haas, Stefan Zeitler
  • VON WILLEBRAND FACTOR OR FACTOR VIII AND VON WILLEBRAND FACTOR FOR THE TREATMENT OF COAGULOPATHY INDUCED BY INHIBITORS OF THROMBOCYTES
    Publication number: 20140128325
    Abstract: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.
    Type: Application
    Filed: November 4, 2013
    Publication date: May 8, 2014
    Applicant: CSL BEHRING GMBH
    Inventors: Gerhard DICKNEITE, Ingo PRAGST, Henrique LESSA, Thorsten HAAS, Stefan ZEITLER
  • FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES
    Publication number: 20140072600
    Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 13, 2014
    Inventors: Stefan Zeitler, Marc Nolte, Stafan Schulte, Gerhard Dickneite, Ingo Pragst
  • von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
    Patent number: 8603979
    Abstract: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: December 10, 2013
    Assignee: CSL Behring GmbH
    Inventors: Gerhard Dickneite, Ingo Pragst, Henrique Lessa, Thorsten Haas, Stefan Zeitler
  • VON WILLEBRAND FACTOR OR FACTOR VIII AND VON WILLEBRAND FACTOR FOR THE TREATMENT OF COAGULOPATHY INDUCED BY INHIBITORS OF THROMBOCYTES
    Publication number: 20110112023
    Abstract: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.
    Type: Application
    Filed: July 10, 2009
    Publication date: May 12, 2011
    Inventors: Gerhard Dickneite, Ingo Pragst, Henrique Lessa, Thorsten Haas, Stefan Zeitler